Excellent editorial, Pradeep. Amazing day for Drs. Ballantyne, Rosenson, and the Arrowhead team with these back to back NEJM publications. This work shows the potential of coupling human genetics (which derisks targets) with powerful siRNA technology. Very promising!

Our Phase 3 study in patients with genetically confirmed or clinically diagnosed FCS successfully met its primary and secondary endpoints. Learn more about our first #RNAi based therapy to show clinical efficacy in a Phase 3 study here: ir.arrowheadpharma.com/news-releases/… $ARWR

Awesome additions to the team! Welcome to Bitterroot you guys - very exciting year ahead and glad to be on this journey with you!

So excited for my son’s first day as a working man! Incredible time meeting his new colleagues for his summer internship with Dodgers Nation. Way to go Jack Leeper! Sports journalism looks good on you!

Having an AAA versus other cardiovascular disease is associated with a higher cancer risk - mechanistic studies are needed. Lingfeng Luo Richard Baylis Shaunak Adkar Nick Leeper @KevinNeadMD Dr. Fu ahajrnls.org/4bMFhs8

Another great collaboration with our colleagues at MD Anderson studying the interface of cancer and cardiovascular diseases. Awesome work from lead post doc, Lingfeng Luo!

Great send off party for two superb postdocs who are finishing their tour of duty in the Leeper lab. So excited for Shaunak Adkar (who will return to his clinical training) and Caitlin Bell (who will be starting her own tenure track lab at the University of Colorado). Good luck!!

See you on The Farm this summer! Showcase your skills and learn from the best while competing at one of our upcoming US Sports Camps summer camps! Register 👉 tinyurl.com/25xf2p4l #GoStanford

Alpha opening things up a bit in the 4th. Jack Leeper (2027, Menlo Park, CA) sends a rising liner that goes to the wall in CF scoring 3. Alpha up 9-0 going to top 5. #UBCWest

Tommy Leeper (29’ AZ) lines a single through the middle. Balance approach at the plate while being on time and in sync. #SeriesTour

Another First-Rounder from The Farm Malcolm Moore is the 35th first-round pick out of Stanford in program history, including the 20th since 2000 🤯 #GoStanford x #MLBDraft

Nice catch Goose!!

30-yard dash, but make it American 🇺🇸

How are the latest cutting-edge #technologies revolutionising #cardiovascular #medicine? Find out in this week's episode of the EMJ #podcast, featuring Nicholas Leeper, @stanford University: hubs.la/Q02LqNRs0

We’re thrilled to attend European Society of Cardiology’s #ESCCongress 2024! Results from our Phase 3 trial of our investigational #RNAi candidate plozasiran will be presented by Dr. Gerald Watts. Learn more here: bit.ly/3WMHcGY

Presented at #ESCardio: In a phase 3 trial involving patients with persistent chylomicronemia, plozasiran, a short interfering RNA that targets APOC3, reduced plasma triglyceride levels and the incidence of pancreatitis. Full PALISADE trial results: nej.md/3YZMBx2

Results from our Phase 3 study of our #RNAi therapy for adults with familial chylomicronemia syndrome were presented at European Society of Cardiology #ESCCongress 2024 and simultaneously published in NEJM. Learn more here: bit.ly/3Tf8uop

Today we announced the U.S. FDA has granted Breakthrough Therapy designation for our #RNAi candidate for familial chylomicronemia syndrome (#FCS). This milestone marks important progress toward bringing potential treatments to patients in need. Learn more: bit.ly/3TlglAI